Showing results (781-790 of 1,302) with videos related to
Sort By:
Pageof 131
Nephrologie & Therapeutique|March 22, 2007
TSC2, a key player in tumor suppression and cystic kidney diseaseSheng-Li Cai, Cheryl Lyn WalkerNephrologie & Therapeutique|March 22, 2007
[Current management of Fabry disease]Pierre Cochat, Aurélia Liutkus, Laurence Dubourg, et al.Nephrologie & Therapeutique|March 22, 2007
[What are the major parameters to follow for the management anaemia in dialysis patients? What is the frequency of survey and what are the guidelines?]Hélène Leray-Moragues, Bernard CanaudNephrologie & Therapeutique|March 22, 2007
[How do we optimally evaluate iron stores in dialyzed patients treated with erythropoiesis stimulating agent?]Michèle Kessler, Sylvain Salignac, Isabelle Aimone-GastinNephrologie & Therapeutique|March 22, 2007
[Factors affecting the response to erythropoiesis-stimulating agents]Maïté Jauréguy, Gabriel ChoukrounNephrologie & Therapeutique|March 22, 2007
[Diagnosis and treatment of pure red-cell aplasia induced by erythropoiesis stimulating agents]Jérôme Rossert, Nicole CasadevallNephrologie & Therapeutique|March 22, 2007
[Iron metabolism pre and post the erythropoietin era]Claude JacobsNephrologie & Therapeutique|March 22, 2007
[Biochemical markers of iron status]Isabelle Aimone-GastinNephrologie & Therapeutique|March 22, 2007
[Iron therapy: is it different with peritoneal dialysis compared to haemodialysis?]Pierre-Yves DurandPageof 131